Successful pemetrexed-containing chemotherapy for epidermal growth factor receptor mutation-positive adenosquamous cell carcinoma of the lung: A case report

Watanabe,Hiroko; Tamura,Tomohiro; Kagohashi,Katsunori; Kawaguchi,Mio; Kurishima,Koichi; Satoh,Hiroaki

doi:10.3892/mco.2016.756

April-2016 Volume 4 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April-2016 Volume 4 Issue 4

Full Size Image

Case Report

Successful pemetrexed-containing chemotherapy for epidermal growth factor receptor mutation-positive adenosquamous cell carcinoma of the lung: A case report

Authors:
- Hiroko Watanabe
- Tomohiro Tamura
- Katsunori Kagohashi
- Mio Kawaguchi
- Koichi Kurishima
- Hiroaki Satoh
View Affiliations / Copyright

Affiliations: Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310-0015, Japan, Division of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8575, Japan, Division of Respiratory Medicine, Tsukuba Medical Center, Tsukuba, Ibaraki 305-8558, Japan
Pages: 628-630
|
Published online on: January 29, 2016

https://doi.org/10.3892/mco.2016.756
Expand metrics +

Abstract

Pemetrexed-containing chemotherapy has shown promise in the treatment of non-small-cell lung cancer (NSCLC). However, although adenosquamous cell lung cancer (ASCLC) is a type of NSCLC, the availability of studies investigating its response to pemetrexed‑containing chemotherapy is limited. A 66‑year‑old woman was referred to Mito Medical Center, University of Tsukuba with hemoptysis and a chest computed tomography (CT) scan revealed a large cavitary mass in the lower lobe of the left lung. The patient underwent left lower lobectomy and mediastinal lymph node dissection. The tumor was staged as pT2bN2M0. An epidermal growth factor receptor (EGFR) exon 19 deletion was identified in the adenocarcinomatous as well as the squamous cell carcinomatous components. Despite gefitinib therapy for pulmonary metastases, the patient developed cavitary metastases in both lungs. Therefore, treatment with pemetrexed‑containing chemotherapy was initiated. a chest CT scan revealed significant regression of the metastatic lesions in both lungs, with thinning of the walls. The patient remains well and recurrence‑free 19 months after the initiation of pemetrexed‑containing chemotherapy. Therefore, the clinical response of EGFR mutation‑positive ASCLC to pemetrexed‑containing chemotherapy was promising, suggesting pemetrexed to be one of the key drugs for this subset of ASCLC patients.

View Figures

View References

1	Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: Pathology and genetics, Tumours of the lung, pleura, thymus and heart. World Health Organization Classification of Tumours (Lyon). IARC Press. 2004.
2	Filosso PL, Ruffini E, Asioli S, Giobbe R, Macri L, Bruna MC, Sandri A and Oliaro A: Adenosquamous lung carcinomas: A histologic subtype with poor prognosis. Lung Cancer. 74:25–29. 2011. View Article : Google Scholar : PubMed/NCBI
3	Shimizu J, Oda M, Hayashi Y, Nomomura A and Watanabe Y: A clinicopathologic study of resected cases of a denosquamous carcinoma of the lung. Chest. 109:989–994. 1996. View Article : Google Scholar : PubMed/NCBI
4	Riquet M, Perrotin C, Lang-Lazdunski L, Hubsch JP, Dujon A, Manac'h D, Le Pimpec Barthes F and Briere J: Do patients with adenosquamous carcinoma of the lung need a more aggressive approach? J Thorac Cardiovasc Surg. 122:618–619. 2001. View Article : Google Scholar : PubMed/NCBI
5	Gawrychowski J, Bruliński K, Malinowski E and Papla B: Prognosis and survival after radical resection of primary adenosquamous lung carcinoma. Eur J Cardiothorac Surg. 27:686–692. 2005. View Article : Google Scholar : PubMed/NCBI
6	Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et al: PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 31:2895–2902. 2013. View Article : Google Scholar : PubMed/NCBI
7	Park JH, Lee SH, Keam B, Kim TM, Kim DW, Yang SC, Kim YW and Heo DS: EGFR mutations as a predictive marker of cytotoxic chemotherapy. Lung Cancer. 77:433–437. 2012. View Article : Google Scholar : PubMed/NCBI
8	Lee SH, Noh KB, Lee JS, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, et al: Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer. 81:102–108. 2013. View Article : Google Scholar : PubMed/NCBI
9	Sánchez Hernández A, José Juan O, Martínez Vidal J, Blanco R, Maciá S, Galiana Esquerdo G, Aparisi Aparisi F, Noguera Garde J, Catot S, Gaspá Losa F and García-Piñon F: Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma. Clin Transl Oncol. 17:281–288. 2015. View Article : Google Scholar : PubMed/NCBI
10	Gazdar AF: Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 28(Suppl 1): S24–S31. 2009. View Article : Google Scholar : PubMed/NCBI
11	Li S, Zhou F, Ren S and Zhou C: Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC. Lung Cancer. 84:203–205. 2014. View Article : Google Scholar : PubMed/NCBI